Propanc Biopharma shares fall 14.57% after-hours after reporting wider Q1 loss of $0.39 vs. $0.36 last year.

Propanc Biopharma (PPCB) fell 14.57% in after-hours trading following the release of its first-quarter 2025/26 results, which showed a wider-than-expected net loss. The company reported Q1 2025/26 earnings per share of -$0.39, compared to -$0.3597 in the prior-year period, signaling deteriorating profitability. This negative earnings surprise, combined with ongoing concerns about the company’s financial health—evidenced by recent smaller fundraising rounds (e.g., a $1M stock sale on November 10)—likely drove the sharp decline. While earlier announcements of a $100M private placement in late October and early November had initially positioned the stock for growth, the latest earnings report overshadowed those developments, prompting investor skepticism about the company’s ability to execute its digital asset and R&D strategies effectively.